Assessment of correlation between cell cycle regulatory protein cyclin D1 expression and prognostic factors in prostate carcinoma

Document Type : Original Article


1 Department of Pathology, Faculty of Medicine, Jundishapur University of Medical Sciences,Ahvaz,Iran

2 Department of pathology, Faculty of Medicine, Jondishapour University of medical Sciences, Ahvaz, Iran

3 Medical student at shahid beheshti univercity of medical science.


Background: The effect of Cyclin D1 expression on prostate cancer has not yet been elucidated. The present study aimed to evaluate the relation of immunohistochemical expression of Cyclin D1 with tumor progression.
Materials and methods: In this descriptive cross-sectional study, tissue samples of patients referred to Imam Khomeini, Shahid Baqaei and Golestan hospitals of Ahwaz with confrimed diagnosis of prostate adenocarcinoma and benign prostatic hyperplasia were used. Clinical and demographic data of patients were extracted from hospital records. Immunohistochemical staining was performed using Anticyclin D1 monoclonal antibody.
Results: In this study, 69 patients with prostate cancer and 10 patients with benign prostatic hyperplasia were studied. Mean age of patients was 70 year. Immunohistochemical expression analysis of Cyclin D1 showed that only 6% of patients were negative and 32% had very strong expression.All of the ten patients with benign prostatic hyperplasia were negative. The high (plus plus) expression of cyclin D1 was significantly more frequent in high grade tumors (p = 0.02).
Conclusion: Overall, the findings of this study indicate that the Cyclin D1 marker is broadly increased in prostate malignancy and its upregulation can be related to tumor grade based on Gleason score .


1-Ross J.S, Jemings T. A, Nazeer T, Shechan Ch. E, Fisher H.A.G, Kauffman R.A, et al. Prognostic Factors in prostate cancer. Am J Clin Pathol. 2003 ; 120 (Suppl 1): S85- S100
2-Boring CC, Squires TS, Tong T. Cancer statistics 1991 [Published Correction appears in CA Cancer J Clin. 1991;41: 111]. CA Cancer J Clin. 1991; 41: 19-36.
3-Seidman H, Mushinski MH, Geib SK, Silverberg E.Probabilities of eventually developing or dying of cancer. CA Cancer J clin.1985;35:36-56.
4-Golblum J.R, Lamps L.W, Mckemey J.K, Myers J.L. ROSAI and ACKERMAN'S SURGICAL PATHOLOGY. 11 th ed. Philadelphia: Elsevier; 2018.
5-Mettlin CJ.Murphy GP,Ho R,et al. The National Cancer Data Base report on longitudinal observations on prostate Cancer. Cancer. 1996; 77: 2162-2166
6-Lu-Yao GL, Gneenberg R.Changes in Prostate Cancer incidence and treatment in USA. Lancet. 1994; 343: 251-254.
7-Cookson MS. Prostate Cancer: Sereening and early detection. Cancer Control. 2001; 8: 133-140
8- Tarone RE,Chu KC, Brawely OW. Implications of Stage- Specific Survival rates in assessing recent declines in Prostate Cancer Mortality rates. Epidemiology. 2000; 11: 167-170
9-Rafiemanesh H,Ghoncheh M, Salehinya H, Moham,Adian Hafshejawi A. Epidbmiology Of Prostate Cancer And Its Incidence Trends In Iran. Journal Of Sabzevar Vniverity Of Medical Sciences. 2016; 23120: 320-327.
10-Pereira R.A, Ravinal R.C, Costa R.S, Lima M.S, Tucci S, Muglia V.F, et al. Cyclin D1 expression in Prostate carcinioma. Braz J Med Biol Res. 2014; 47 (6): 515- 521.
11-Chen X, Miao Z, Divate M, Zhao Z, Cheung E. KM-express: an integrated online patient survival and gene expression analysis tool for the identification and functional characterization of prognostic markers in breast and prostate cancers. Database. 2018 Jan 1;2018
12-Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. Journal of cellular physiology. 2009 Aug;220(2):292-6.
13-Comstock CES, Revelo MP, Buncher CR, Knudsen KE. Impact of defferential cyclin D1 expression and localization in Prostate Cancer. British Journal of cancer. 2007; 96: 970-979
14-”¶ZBEK E, MIZRAK B, ”¶ZBEK M, BÜYÜKBERBER S, DAVARCL M. Cyclin D1 Protooncogen expressiom in Prostate Cancer. Cyclin-V1 Protooncogen expression in prostate cancer. Turkish Journal of cancer. 2000; 30 (1): 15-23
15-Dunsmuir W.D, Gillett C.E, Meyer  L.C,Young M.P, Corbishley C, Eeles R.A, et al. Molecular markets for Pnedicting Prostate Cancer Stage and Survival . BJV International. 2000; 86: 869-878.
16-Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clinical Cancer Research. 2000 May 1;6(5):1891-5.
17-Gupta V, Singh S, Sen R, Gill M, Sangwaiya A, Garg M, Chaudhry M. Role of cyclin D1 immunoreactivity and AgNOR staining in the evaluation of benign and malignant lesions of the prostate. Prostate international. 2014 Jun 1;2(2):90-6.